The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

Drug Intelligence & Clinical Pharmacy: Vol. 16, No. 5, pp. 387-390.
© 1982 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gaskins, J.
Right arrow Articles by Ward, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gaskins, J.
Right arrow Articles by Ward, J

Research Articles

Chemoprophylaxis of recurrent otitis media using trimethoprim/sulfamethoxazole

JD Gaskins, RJ Holt, CU Kyong, CW Weart, and J Ward

This study was undertaken during the late fall, winter, and early spring months to determine the efficacy of daily trimethoprim/sulfamethoxazole (TMP/SMX) administration in the prevention of recurrent acute otitis media (RAOM) in a specific high-risk pediatric population. Twenty-one ambulatory patients, 10 in the study group and 11 in the control group, were selected from a medical university clinic and a local private practice. The study group receiving prophylactic therapy for six months suffered no recurrences, as compared with eight children suffering one recurrence each in the control group that was treated only acutely. The results were significant at p less than 0.005 with df = 1, determined by the Fischer's exact test and the chi-square method using Yates's correction factor. These data indicated that a mean dose of TMP/SMX 6.8/34 mg/kg/d divided into twice daily doses and given for six months was safe and effective in controlling RAOM infections in a high-risk pediatric population.


This article has been cited by other articles:


Home page
 PediatricsHome page
E. L. van der Veen, M. M. Rovers, F. W. J. Albers, E. A. M. Sanders, and A. G. M. Schilder
Effectiveness of Trimethoprim/Sulfamethoxazole for Children With Chronic Active Otitis Media: A Randomized, Placebo-Controlled Trial
Pediatrics, May 1, 2007; 119(5): 897 - 904.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
P. A. Masters, T. A. O'Bryan, J. Zurlo, D. Q. Miller, and N. Joshi
Trimethoprim-Sulfamethoxazole Revisited
Arch Intern Med, February 24, 2003; 163(4): 402 - 410.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. F. Dowell, S. M. Marcy, W. R. Phillips, M. A. Gerber, and B. Schwartz
Otitis Media---Principles of Judicious Use of Antimicrobial Agents
Pediatrics, January 1, 1998; 101(1): 165 - 171.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
M. J. Cunningham
Chemoprophylaxis with Oral Trimethoprim-sulfamethoxazole In Otitis Media: Relevance of Hematologic Abnormalities
Clinical Pediatrics, May 1, 1990; 29(5): 273 - 277.
[Abstract] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1982 by Harvey Whitney Books Company.